Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: ‘A Journey To Focus On Data And Digital’ – Forbes
Forbes |
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'
Forbes This morning, Novartis announced it would buy gene therapy pioneer AveXis for $8.7 billion, giving the Swiss drug giant several treatments for rare diseases that work by inserting new DNA into patients' cells. AveXis shares rose 78% to nearly match the … Why the Deal for AveXis Is a Powerful Vote for Replacement Gene Therapy Why Novartis Is Paying $8.7 Billion for a Gene Therapy Developer You've Never Heard Of Novartis enters deal to acquire gene therapy company AveXis for $8.7 billion |
